- Conditions
- Burns, Second Degree Burn, Wounds and Injuries
- Interventions
- Drug: 4-Aminopyridine, Placebo
- Drug · Other
- Lead sponsor
- John Elfar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 72
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Congenital Myasthenic Syndrome
- Interventions
- 3,4-Diaminopyridine
- Drug
- Lead sponsor
- Ricardo Maselli
- Other
- Eligibility
- 3 Months to 75 Years
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Spinal Muscular Atrophy
- Interventions
- 4-aminopyridine, Placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Spinocerebellar Ataxias Type 1, Spinocerebellar Ataxias Type 2, Spinocerebellar Ataxias Type 3, Spinocerebellar Ataxias Type 6
- Interventions
- Dalfampridine, Placebo
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Parkinson's Disease
- Interventions
- Ampyra first, then Placebo, placebo first, then Ampyra
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Sleep Apnea, Obstructive
- Interventions
- Placebo, Dalfampridine
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Botulism, Iatrogenic Botulism
- Interventions
- Amifampridine
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Ischemic Stroke
- Interventions
- placebo/dalfampridine-ER, dalfampridine-ER/placebo
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • La Jolla, California • Newport Beach, California + 17 more
- Conditions
- Non Arteritic Ischemic Optic Neuropathy
- Interventions
- dalfampridine, Placebo
- Drug
- Lead sponsor
- Neuro-Ophthalmologic Associates, PC
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Post-ischemic Stroke
- Interventions
- dalfampridine-ER 7.5 mg, dalfampridine-ER 10 mg
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 62
- States / cities
- Gilbert, Arizona • Berkeley, California • Carlsbad, California + 54 more
- Conditions
- Myasthenic Syndromes, Congenital
- Interventions
- amifampridine phosphate, Placebo
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Spinal Cord Injury, Muscle Spasticity
- Interventions
- Fampridine-SR, Placebo
- Drug · Other
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more
- Conditions
- Multiple Sclerosis
- Interventions
- Fampridine-SR, Placebo
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography
- Procedure · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1655
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more
- Conditions
- Multiple Sclerosis
- Interventions
- Dalfampridine-ER 5mg, Dalfampridine-ER 10mg, Placebo
- Drug · Other
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 70
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 59 more
- Conditions
- Multiple Sclerosis, Fatigue
- Interventions
- Dalfampridine, Placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 20 Years to 59 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Multiple Sclerosis, Internuclear Ophthalmoplegia, Fatigue
- Interventions
- Dalfampridine, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Multiple Sclerosis
- Interventions
- dalfampridine ER, placebo
- Drug
- Lead sponsor
- Brown, Theodore R., M.D., MPH
- Individual
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Kirkland, Washington
- Conditions
- Multiple Sclerosis
- Interventions
- Dalfampridine 10 MG [Ampyra], Physical therapy, Dalfampridine plus physical therapy
- Drug · Behavioral · Other
- Lead sponsor
- MGH Institute of Health Professions
- Other
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
- Interventions
- Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6,452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1405
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
- Conditions
- SCI - Spinal Cord Injury
- Interventions
- Dalfampridine, Placebo, STDP stimulation, Exercise training
- Drug · Other · Behavioral
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Myasthenic Syndromes, Congenital
- Interventions
- 3,4-diaminopyridine
- Drug
- Lead sponsor
- Vern C. Juel, M.D.
- Other
- Eligibility
- Not listed
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Multiple Sclerosis
- Interventions
- Fampridine-SR, Placebo
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 31 more
- Conditions
- Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Radiation Therapy, Carboplatin, Cisplatin, Crizotinib, Erlotinib, Etoposide, Paclitaxel
- Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 174
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 137 more